Genmab Net Receivables from 2010 to 2026
| GE9 Stock | EUR 280.00 1.20 0.43% |
Net Receivables | First Reported 2016-12-31 | Previous Quarter 6.1 B | Current Value 4.8 B | Quarterly Volatility 1.8 B |
Check Genmab A/S financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Genmab A/S's main balance sheet or income statement drivers, such as Discontinued Operations of 33.8 M, Interest Expense of 0.0 or Selling General Administrative of 413 M, as well as many indicators such as Price To Sales Ratio of 4.9, Dividend Yield of 0.0 or PTB Ratio of 2.25. Genmab financial statements analysis is a perfect complement when working with Genmab A/S Valuation or Volatility modules.
Genmab | Net Receivables |
The Net Receivables trend for Genmab AS offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Genmab A/S is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Genmab A/S's Net Receivables Growth Pattern
Below is the plot of the Net Receivables of Genmab AS over the last few years. It is Genmab A/S's Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Genmab A/S's overall financial position and show how it may be relating to other accounts over time.
| Net Receivables | 10 Years Trend |
|
Net Receivables |
| Timeline |
Genmab Net Receivables Regression Statistics
| Arithmetic Mean | 2,664,283,912 | |
| Geometric Mean | 1,028,820,337 | |
| Coefficient Of Variation | 103.73 | |
| Mean Deviation | 2,378,197,201 | |
| Median | 1,327,000,000 | |
| Standard Deviation | 2,763,547,705 | |
| Sample Variance | 7637195.9T | |
| Range | 7.2B | |
| R-Value | 0.94 | |
| Mean Square Error | 972668.4T | |
| R-Squared | 0.88 | |
| Slope | 513,554,294 | |
| Total Sum of Squares | 122195134.7T |
Genmab Net Receivables History
About Genmab A/S Financial Statements
Genmab A/S stakeholders use historical fundamental indicators, such as Genmab A/S's Net Receivables, to determine how well the company is positioned to perform in the future. Although Genmab A/S investors may analyze each financial statement separately, they are all interrelated. For example, changes in Genmab A/S's assets and liabilities are reflected in the revenues and expenses on Genmab A/S's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Genmab AS. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Receivables | 7 B | 7.3 B |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of Genmab A/S Correlation against competitors. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.